News|Articles|November 17, 2026

Adrabetadex Becomes First Therapy Shown to Extend Survival in Infantile-Onset Niemann-Pick Disease Type C

Listen
0:00 / 0:00

Key Takeaways

  • FDA approval covers adult and pediatric I-NPC (≥7 kg) with neurologic onset <6 years, marking the first intervention shown to prolong survival in this high-mortality phenotype.
  • Mechanistically, adrabetadex (2-hydroxypropyl-β-cyclodextrin isomer mixture) targets impaired intracellular cholesterol trafficking, administered intrathecally every two weeks by trained clinicians.
SHOW MORE

Adrabetadex cut the risk of death by 55%, but its boxed warning for permanent hearing loss means patients need regular hearing tests.

The FDA approved adrabetadex (Lembaz; Beren Therapeutics) injection to reduce the risk of death in adult and pediatric patients weighing at least 7 kg who have Niemann-Pick disease type C (NPC) with neurologic symptoms that began before 6 years of age, also known as infantile-onset NPC (I-NPC). It is the first treatment shown to help patients with this severe form of the disease live longer.1

"For the first time, there is a treatment shown to help adults and children with this serious disease live longer," said Acting FDA Commissioner Kyle Diamantas, JD, in a news release.1

For pharmacists, the hearing monitoring matters as much as the survival data. The drug carries a boxed warning for hearing impairment, including permanent hearing loss, and its dose is adjusted based on repeated hearing tests.1,2

Targeting the Underlying Defect

NPC is a rare, inherited lysosomal storage disorder affecting an estimated 1 in 150,000 individuals, in which cells cannot properly process cholesterol and other lipids. These substances accumulate, particularly in the brain, driving progressive loss of movement, coordination, and the ability to swallow.1 Mean age at death is approximately 5.6 years for patients with neurologic onset before age 2 years and 13.4 years for those with onset from age 2 to younger than 6 years.2

Two therapies were previously approved for NPC, including arimoclomol (Miplyffa; Zevra Therapeutics) in combination with miglustat.3 Neither has been shown to reduce the risk of death, and both carry age and weight restrictions that limit access for the youngest, most seriously affected patients.1 Adrabetadex, a mixture of 2-hydroxypropyl-β-cyclodextrin isomers, is designed to restore intracellular cholesterol trafficking, addressing the disease's underlying defect.2 A trained health care provider administers it intrathecally every 2 weeks.1

An Externally Controlled Survival Analysis

The FDA evaluated survival in 36 patients with I-NPC treated with adrabetadex across 3 clinical studies (NCT02534844, NCT03643562, NCT04958642) and an expanded access program, compared with a matched external control group. Treatment was associated with a 55% reduction in the risk of death, with a median overall survival of 8.5 years vs 4.9 years in controls. The benefit was observed regardless of concomitant miglustat use, which is off-label in NPC.1

Safety Centers on Hearing

Permanent hearing impairment, ranging from mild to profound, has occurred with adrabetadex—including in patients whose hearing was normal before treatment. Baseline audiology, including pure tone audiometry, speech recognition, and tympanometry, is required. Hearing is retested 1 to 2 weeks after the first and second doses at each dosage level, before the next dose; once the dose is stable or at maximum, testing shifts to monthly, then every 12 months. The dose is not increased if testing shows impairment beyond set limits.2

Ataxia and fatigue carry separate warnings. Both typically emerge within days of a dose and have required hospitalization in severe cases. Other common adverse reactions include vomiting, back pain, headache, fever, diarrhea, nausea, and cough.1,2

What Pharmacists Should Watch

With biweekly intrathecal dosing at treatment sites, health-system and specialty pharmacists will be involved in every dosing cycle. Practical touchpoints include confirming that audiology results are in hand before titration, preparing caregivers for postdose unsteadiness and fall risk, and flagging when severe ataxia or fatigue warrants a call. Beren expects availability at sites nationwide in early December, with a family access program offering site coordination and out-of-pocket assistance for eligible patients.2

REFERENCES
1. FDA approves first drug shown to help patients with infantile-onset Niemann-Pick disease type C live longer. News release. FDA. November 17, 2026. Accessed November 17, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-shown-help-patients-infantile-onset-niemann-pick-disease-type-c-live-longer
2. Beren Therapeutics announces US FDA approval of Lembaz (adrabetadex), first & only medicine to improve survival in infantile-onset Niemann-Pick disease, type C. News release. Beren Therapeutics. November 17, 2026. Accessed November 17, 2026. https://www.financialcontent.com/article/bizwire-2026-11-17-beren-therapeutics-announces-us-fda-approval-of-lembaz-adrabetadex-first-and-only-medicine-to-improve-survival-in-infantile-onset-niemann-pick-disease-type-c
3. FDA approves first treatment for Niemann-Pick disease, type C. News release. FDA. September 20, 2024. Accessed November 17, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-niemann-pick-disease-type-c

Related to this article